WESTPORT, Conn.–(BUSINESS WIRE)–Advanced BioHealing, Inc. (ABH), a leader in commercializing the promise of regenerative medicine, announced a strategic growth plan designed to continue the transformation of this former start-up into the leading international regenerative medicine company. Since 2006, ABH has grown revenue from zero to a projected $80 million by year-end 2009 and today employs more than 200 professionals. The Company manufactures and markets Dermagraft®, a bio-engineered skin substitute that repairs tissue damaged by disease or injury and supports the body’s natural healing process in patients with diabetic foot ulcers.
To spur future growth, executive management has outlined a growth strategy to leverage current successes, develop its international presence, address new applications, and expand its product line.
“Advanced BioHealing has a significant opportunity in the field of regenerative medicine,” said Kevin Rakin, Chairman and Chief Executive Officer. “Having proven the viability of our technology and having achieved commercial success for our lead product in treating diabetic foot ulcers, we are now looking at additional applications and new growth markets to pursue.”
Rakin continued, “For many years, we and others in our industry have touted the significance of living cell technologies and regenerative medicine. While progress has been made on the scientific and medical fronts, only a handful of companies have been able to execute a successful commercialization strategy. ABH has been at the forefront. Today we stand among the best in the world at commercializing a living cell technology and have ambitious plans for continued domestic and international growth.”